| Theme | New Drugs for Dialysis Patients | |
|---|---|---|
| Title | Infectious disease | |
| Publish Date | 2006/06 | |
| Author | Takashi Harada | Department of Blood Purification, Nagasaki University Hospital, School of Medicine and Dentistry |
| Author | Masafumi Seki | Department of Respiratory Medicine, Nagasaki University, Graduate School of Biomedical Sciences |
| Author | Masaharu Nishikido | Department of Blood Purification, Nagasaki University Hospital, School of Medicine and Dentistry |
| Author | Shigeru Kohno | Department of Respiratory Medicine, Nagasaki University, Graduate School of Biomedical Sciences |
| [ Summary ] | In the field of infection control, new antibiotic agents are needed for treatment of resistant bacteria. The development of new antibiotic agents with strong antibacterial actions and minimal adverse reactions is also needed. Linezolid, telithromycin, doripenem and moxifloxacin were developed to combat vancomycin resistant gram positive micrococcus, penicillin, cefem and macroraid resistant pneumococcus and pneumococcus organisms. Micafungin, voriconazole and amphotericin B lipid complex have been developed to treat deep fungal infections. Pneumococcal polysaccharide vaccin is used for prevention of pneumococcus infections. Lamivudine and adefovir are widely used for treatment of chronic hepatitis B. Pegylated interferon plus ribavirin treatment has now become the treatment of choice for this disease. Ivermectin is used now as the first choice for treatment of sarcoptes scabiei. |
|